TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
Crohn's disease
DR3
Inflammatory Bowel Diseases
TL1A
Ulcerative colitis
anti-TL1A
fibrosis
inflammation
mucosal immune system
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
07
2020
revised:
05
08
2020
accepted:
27
08
2020
pubmed:
22
1
2021
medline:
30
11
2021
entrez:
21
1
2021
Statut:
ppublish
Résumé
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. In the last few years, the development of biological agents targeting cytokines and receptors involved in IBD pathogenesis has led to better outcomes and has improved the course of the disease. Despite their effectiveness, drugs such as tumor necrosis factor (TNF) inhibitors, anti-Interleukin-12/23 and anti-integrins, do not induce a response in about one-third of patients, and 40% of patients lose response over time. Therefore, more efficient therapies are required. Recent studies showed that TL1A (Tumor necrosis factor-like cytokine 1A) acts as a regulator of mucosal immunity and participates in immunological pathways involved in the IBD pathogenesis. In this review article, we analyze the role of TL1A as a new potential target therapy in IBD patients.
Identifiants
pubmed: 33475057
pii: CDT-EPUB-113507
doi: 10.2174/1389450122999210120205607
doi:
Substances chimiques
TNFSF15 protein, human
0
Tumor Necrosis Factor Ligand Superfamily Member 15
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
760-769Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.